Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 08/24 03:38:02 pm
174.77 USD   +0.21%
08/23 AMGEN : New data adds to understanding of Repatha® (evolocumab) in m..
08/22 AMGEN : New Data Add To Understanding Of Repatha(R) (Evolocumab) In ..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
08/23 AMGEN : New data adds to understanding of Repatha® (evolocumab) in multiple pati..
08/22 AMGEN : New Data Add To Understanding Of Repatha(R) (Evolocumab) In Multiple Pat..
08/22DJEli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/19 AMGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
08/18 AMGEN : Ayotte – Reilly
08/17 AMGEN : Attending the 2016 U.S. Amgen Scholar Symposium
08/17 AMGEN : Assigned Patent
08/15 AMGEN : A Look Inside Amgen Biotech Experience Labs
08/15 AMGEN, INC. : ex-dividend day
08/12 AMGEN : Launches Commercial Office in Hong Kong
More news
Sector news : Bio Therapeutic Drugs
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 4th Update
08/22DJPFIZER : to Acquire Medivation in Deal Worth $14 Billion -- 3rd Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/22 Why I Didn't Buy Gilead, Apple Or 100 Others, Y'all - Part 3
08/22 Amgen undeterred with cholesterol fighter Repatha; 11 abstracts on tap for up..
08/21 MY PORTFOLIO UPDATE AND REVIEW OF 83 : Up 2 With Reynolds And Exelon, Down 1 Wit..
08/19 U.S. V. Apple - The Looming Trial Of The Century?
08/19 5 Golden Rules For Better Biotech Investing
Financials ($)
Sales 2016 22 781 M
EBIT 2016 11 110 M
Net income 2016 7 460 M
Debt 2016 3 339 M
Yield 2016 2,24%
P/E ratio 2016 17,65
P/E ratio 2017 16,29
EV / Sales 2016 5,88x
EV / Sales 2017 5,43x
Capitalization 130 514 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 191 $
Spread / Average Target 9,7%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.7.44%130 514
GILEAD SCIENCES, INC.-19.49%107 513
ACTELION LTD17.62%18 523
More Results